Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0140-6736(83)90549-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transient ischemic attack in a patient with congenital protein-C deficiency during treatment with stanozolol.
Am J Hematol
October 1988
Istituto di Semeiotica Medica, Università Cattolica del S. Cuore, Roma, Italy.
A patient with congenital protein-C deficiency was treated with stanozolol for 8 weeks to increase circulating levels of protein C. A rise in protein C was achieved, accompanied by an increase in factor II, factor X, antithrombin III, and protein S; but at the 8th week the patient suffered a transient ischemia attack.
View Article and Find Full Text PDFHemostatic abnormalities in nephrotic syndrome.
Vet Clin North Am Small Anim Pract
January 1988
Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine and Animal Sciences, University Pertanian Malaysia, Serdang, Selangor.
Nephrotic syndrome is often associated with a hypercoagulable state and thrombotic complications. Thrombosis may be due to a number of abnormalities in blood, including AT III deficiency, increased concentrations of fibrinogen, factors V and VIII, and platelet hyperaggregability. The therapeutic approach to thrombosis in nephrotic syndrome is the use of anticoagulants as a preventive measure or an attempt at thrombolysis with streptokinase, urokinase, or stanozolol.
View Article and Find Full Text PDFFive type I protein C deficient male patients received 5 mg stanozolol b.i.d.
View Article and Find Full Text PDFIn an antithrombin-III (AT-III) deficient patient suffering from recurrent episodes of venous and arterial thrombosis requiring major surgery an attempt was made to institute antithrombotic protection by long-term stanozolol treatment supplemented during periods of thrombogenic exposure with subcutaneous heparin and, when needed, infusion of AT-III as plasma or concentrate. Stanozolol raised the plasma levels of AT-III, demonstrating a sparing effect on the AT-III needed. Despite the repeated exposures to major surgery, protection against venous thrombosis was complete, but the arterial disease progressed and led to the demise of the patient.
View Article and Find Full Text PDFPlasminogen, fibrinogen, antithrombin III, euglobulin lysis time, tissue plasminogen activator (t-PA) and fast-acting t-PA inhibitor were measured in 21 patients receiving either stanozolol (10 mg orally given for 14 days preoperatively) or subcutaneous heparin, during a continuing comparative trial in the prevention of postoperative deep vein thrombosis. Stanozolol treatment resulted in significant (p less than 0.01) increases between the 14th and 1st preoperative days in the plasma concentrations of plasminogen (3.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!